Active, not recruitingPHASE1, PHASE2NCT06283212
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
Studying Dravet syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Encoded Therapeutics
- Principal Investigator
- Salvador Rico, M.D., Ph. DEncoded Therapeutics
- Intervention
- ETX101(drug)
- Enrollment
- 5 enrolled
- Eligibility
- All sexes
- Timeline
- 2024 – 2030
Study locations (3)
- Queen Elizabeth Hospital, Glasgow, United Kingdom
- Great Ormond Street Hospital, London, United Kingdom
- Sheffield Children's Hospital, Sheffield, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06283212 on ClinicalTrials.govOther trials for Dravet syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07251673Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene MutationAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE3NCT06872125A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeStoke Therapeutics, Inc
- RECRUITINGPHASE4NCT06598449Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of AgeUniversity of Colorado, Denver
- RECRUITINGPHASE3NCT06660394A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Longboard Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE3NCT06118255A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromeUCB BIOSCIENCES, Inc.
- RECRUITINGPHASE1, PHASE2NCT05419492A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromeEncoded Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06112275A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)Encoded Therapeutics
- ENROLLING BY INVITATIONNANCT06371794EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype HeterogeneityFondazione Policlinico Universitario Agostino Gemelli IRCCS